Inhibikase Therapeutics, Inc. (IKT) Form 8-K — Oct 20, 2026
Inhibikase Therapeutics (Nasdaq: IKT) announced on October 20, 2026 that Scott Wasserman, MD, has been appointed to its Board of Directors, effective October 19, 2026. Dr. Wasserman is Chief Medical Officer of Kailera Therapeutics and a cardiologist with two decades of clinical development experience, including leading development of Amgen's Repatha. Concurrent with the appointment, director Dennis Berman resigned from the Board and his role as Compensation Committee Chair.
Key figures
- Director term
- Class III director until 2029 annual meeting
- New director option grant shares
- 310000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.